{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:46:14Z","timestamp":1777509974486,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD Animal Health Innovation GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a demand for broad-spectrum products effective against internal and external parasites to simplify dog-owner compliance with veterinary parasiticide treatment recommendations. A field study investigated the safety and efficacy of a broad-spectrum formulation of fluralaner, moxidectin, and pyrantel pamoate compared with a licensed afoxolaner\u2013milbemycin oxime combination product in treating canine intestinal nematode infections in client-owned dogs at multiple sites in Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Dogs with positive pre-treatment fecal egg counts (FEC) were randomized to treatment on day 0 with the investigative veterinary product (IVP), at dose rates of: IVP, fluralaner 10\u201320\u00a0mg\/kg, moxidectin 0.025\u20130.050\u00a0mg\/kg, pyrantel 5\u201310\u00a0mg\/kg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009172); or a control product (CP), afoxolaner 2.5\u20135.2\u00a0mg\/kg, milbemycin oxime 0.5\u20131.0\u00a0mg\/kg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200986). On day 14, FEC were completed on all study dogs. Efficacy against any intestinal nematode species was claimed if the FEC reduction in\u2009\u2265\u200910 dogs initially positive for that species was\u2009\u2265\u200990%, and if the geometric mean difference between pre- and post-treatment FEC was statistically significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009\u2264\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Study dogs were enrolled at veterinary clinics in Albania (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200960), Bulgaria (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009111), Greece (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), and Italy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200960). Where a sufficient number of infected dogs allowed for statistical comparison, geometric mean FEC reductions on day 14 versus day 0 in the IVP group were significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) for hookworms,\n                      <jats:italic>Toxocara canis<\/jats:italic>\n                      ,\n                      <jats:italic>Toxascaris leonina, Trichuris vulpis<\/jats:italic>\n                      , and capillarid-type eggs. On the basis of geometric mean reductions in FEC relative to day 0, the efficacy of the IVP exceeded 99% against all intestinal nematode parasites, and FEC reductions in the CP exceeded 98%. The percentage of nematode-free dogs in the IVP group was statistically noninferior (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) to the CP group and even statistically superior at the\n                      <jats:italic>\u03b1<\/jats:italic>\n                      \u2009=\u20090.025 level of significance (one-sided). There were no treatment-related adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In client-owned dogs, the combination of fluralaner\u2013moxidectin\u2013pyrantel is safe and effective for the treatment of intestinal infections with hookworms, ascarids, including\n                      <jats:italic>T.\u00a0canis<\/jats:italic>\n                      , and whipworms. On the basis of the complete elimination of parasite ova from the feces evaluated in this study, this fluralaner\u2013moxidectin\u2013pyrantel combination demonstrated to be significantly superior (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.025) to an afoxolaner\u2013milbemycin combination in the treatment of canine intestinal nematode infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-026-07348-7","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:03:59Z","timestamp":1775149439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Field study evaluating the efficacy of a combination formulation of fluralaner with moxidectin and pyrantel (BRAVECTO\u00ae TriUNO) against canine intestinal nematode infections"],"prefix":"10.1186","volume":"19","author":[{"given":"Rafael","family":"Chiummo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Zschiesche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvezdelina","family":"Kirkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Otranto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Bezerra-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhimiter","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Heinau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"7348_CR1","volume":"10","author":"C Sherlock","year":"2023","unstructured":"Sherlock C, Holland CV, Keegan JD. Caring for canines: a survey of dog ownership and parasite control practices in Ireland. Vet Sci. 2023;10:90.","journal-title":"Vet Sci"},{"key":"7348_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ani14030450","volume":"14","author":"A Tylkowska","year":"2024","unstructured":"Tylkowska A, Mocha N, Ko\u0142nierzak MM, Szenejko M. Risk factors associated with soil-transmitted helminths in dog feces that contaminate public areas of Warsaw, Poland. Animals. 2024;14:450.","journal-title":"Animals"},{"key":"7348_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04147-6","volume":"13","author":"K Stafford","year":"2020","unstructured":"Stafford K, Kollasch TM, Duncan KT, Horr S, Goddu T, Heinz-Loomer C, et al.\u00a0Detection of gastrointestinal parasitism at recreational canine sites in the USA: the DOGPARCS study. Parasit Vectors. 2020;13:348.","journal-title":"Parasit Vectors"},{"key":"7348_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-022-05440-2","volume":"15","author":"J Drake","year":"2022","unstructured":"Drake J, Sweet S, Baxendale K, Hegarty E, Horr S, Friis H, et al. Detection of Giardia and helminths in Western Europe at local K9 (canine) sites (DOGWALKS Study). Parasit Vectors. 2022;15:311.","journal-title":"Parasit Vectors"},{"key":"7348_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-020-04086-2","volume":"13","author":"C Pennelegion","year":"2020","unstructured":"Pennelegion C, Drake J, Wiseman S, Wright I. Survey of UK pet owners quantifying internal parasite infection risk and deworming recommendation implications. Parasit Vectors. 2020;13:218.","journal-title":"Parasit Vectors"},{"key":"7348_CR6","unstructured":"FDA-NADA 141\u2013532. BRAVECTO\u00ae 1-Month. Freedom of Information Summary. 2020. https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/9329 Accessed 4 Mar 2025."},{"key":"7348_CR7","unstructured":"EMA. BRAVECTO. Summary of Product Characteristics"},{"key":"7348_CR8","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2460\/javma.1995.206.11.1710","volume":"206","author":"CR Reinemeyer","year":"1995","unstructured":"Reinemeyer CR, Faulkner CT, Assadi-Rad AM, Burr JH, Patton S. Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups. J Am Vet Med Assoc. 1995;206:1710\u20135.","journal-title":"J Am Vet Med Assoc"},{"key":"7348_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5326\/JAAHA-MS-6904","volume":"55","author":"LB Hess","year":"2019","unstructured":"Hess LB, Millward LM, Rudinsky A, Vincent E, Marsh A. Combination anthelmintic treatment for persistent Ancylostoma caninum ova shedding in greyhounds. J Am Anim Hosp Assoc. 2019;55:160\u20136.","journal-title":"J Am Anim Hosp Assoc"},{"key":"7348_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2024.1460452","volume":"11","author":"C Raw","year":"2024","unstructured":"Raw C, Traub RJ, Wiethoelter A. A comparative field efficacy trial of three treatment programs against endo- and ectoparasites in naturally infected dogs. Front Vet Sci. 2024;11:1460452.","journal-title":"Front Vet Sci"},{"key":"7348_CR11","unstructured":"EMA. NexGard Spectra. Summary of Product Characteristics. 2023."},{"key":"7348_CR12","unstructured":"EMA. Credelio Plus. Summary of Product Characteristics. 2021."},{"key":"7348_CR13","first-page":"179","volume-title":"Proc Am Heartworm Soc","author":"RR King","year":"1992","unstructured":"King RR, Courtney CH, Aguilar R. Heartworm prophylaxis with moxidectin: field trial results from a hyperenzootic area. In: Soll MD, editor. Proc Am Heartworm Soc. Austin TX: American Heartworm Society; 1992. p. 179\u201382."},{"key":"7348_CR14","unstructured":"FDA NADA #141\u2013251. Advantage Multi Prescribing Information. 2023"},{"key":"7348_CR15","unstructured":"FDA NADA #141\u2013581. Credelio Quattro Prescribing Information. 2024"},{"key":"7348_CR16","unstructured":"EMA. Simparica Trio. Summary of Product Characteristics. 2024."},{"key":"7348_CR17","unstructured":"Rohdich N, Chiummo R, Zschiesche E, Raulf MK,  Schwarz A, McLoughlin A, Schnyder M, Schulte Bocholt J, Merhof K, Miki\u0107 M, Strube C, Heinau L. Efficacy of a single orally administered formulation of fluralaner, moxidectin and pyrantel (BRAVECTO\u00ae TriUNO) in dogs for the treatment and prevention of angiostrongylosis. Parasit Vectors. Manuscript submitted for publication."},{"key":"7348_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-025-07232-w","author":"L Heinau","year":"2026","unstructured":"Heinau L, Petersen I, Rohdich N, Plehn C, Chiummo R, Zschiesche E, et al. Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTO\u00aeTriUNO) against hookworm and Toxascaris leonina infections in a non-terminal study design in dogs. Parasit Vectors. 2026;3;19:90.","journal-title":"Parasit Vectors"},{"key":"7348_CR19","unstructured":"EMA. Guideline on good clinical practices. VICH Topic GL9. 2000. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/vich-gl9-good-clinical-practices-step-7_en.pdf Accessed 4 Feb, 2026."},{"key":"7348_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2022.109815","volume":"312","author":"F Beugnet","year":"2022","unstructured":"Beugnet F, Taweethavonsawat P, Traversa D, Fourie J, McCall J, Tielemans E, et al. \u00a0World Association for the Advancement of Veterinary Parasitology (WAAVP): second edition of guidelines for evaluating the efficacy of anthelmintics for dogs and cats. Vet Parasitol. 2022;312:109815.","journal-title":"Vet Parasitol"},{"key":"7348_CR21","unstructured":"EMA. Guideline on good clinical practices. VICH Topic GL7. 2024. https:\/\/www.ema.europa.eu\/en\/vich-gl7-efficacy-anthelmintics-general-requiremnts-scientific-guideline. Accessed 7 Apr 2025."},{"key":"7348_CR22","unstructured":"EMA. Guideline on statistical principles for veterinary clinical trials. 2002."},{"key":"7348_CR23","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/nprot.2017.067","volume":"12","author":"G Cringoli","year":"2017","unstructured":"Cringoli G, Maurelli MP, Levecke B, Bosco A, Vercruysse J, Utzinger J, et al. \u00a0The mini-FLOTAC technique for the diagnosis of helminth and protozoan infections in humans and animals. Nat Protoc. 2017;12:1723\u20131732.","journal-title":"Nat Protoc"},{"key":"7348_CR24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/sim.4780091208","volume":"9","author":"CP Farrington","year":"1990","unstructured":"Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447\u201354.","journal-title":"Stat Med"},{"key":"7348_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2024.110249","volume":"330","author":"S Illiano","year":"2024","unstructured":"Illiano S, Ciuca L, Bosco A, Rinaldi L, Maurelli MP. Comparison of different molecular protocols for the detection of Uncinaria stenocephala infection in dogs. Vet Parasitol. 2024;330:110249.","journal-title":"Vet Parasitol"},{"key":"7348_CR26","unstructured":"European Scientific Counsel Companion Animal Parasites. ESCCAP guideline 01: worm control in dogs and cats, 6th edition; 2021. https:\/\/www.esccap.org\/guidelines\/. Accessed 7 Apr 2025."},{"key":"7348_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s11686-021-00509-x","volume":"67","author":"G \u0160trkolcov\u00e1","year":"2022","unstructured":"\u0160trkolcov\u00e1 G, Mravcov\u00e1 K, Mucha R, Mulinge E, Schreiberov\u00e1 A. Occurrence of hookworm and the first molecular and morphometric identification of Uncinaria stenocephala in dogs in Central Europe. Acta Parasitol. 2022;67:764\u201372.","journal-title":"Acta Parasitol"},{"key":"7348_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2460\/ajvr.1991.52.01.64","volume":"52","author":"DD Bowman","year":"1991","unstructured":"Bowman DD, Lin DS, Johnson RC, Hepler DI. Effects of milbemycin oxime on adult Ancylostoma caninum and Uncinaria stenocephala in dogs with experimentally induced infections. Am J Vet Res. 1991;52:64\u20137.","journal-title":"Am J Vet Res"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-026-07348-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:36:07Z","timestamp":1777390567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13071-026-07348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7348"],"URL":"https:\/\/doi.org\/10.1186\/s13071-026-07348-7","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with local and national regulations, study permits were obtained from the respective national authorities of Albania (Ministry of Agriculture and Rural Development, National Authority of Veterinary and Plant Protection, Regional Directorate of Veterinary and Plant Protection) under protocol no. 253, S20164-00, Bulgaria (Ministry of Agriculture, Foods and Forests, Bulgarian Food Safety Agency) under document no. 313, Greece (EOF-National Organization for Medicines) under protocol no. 65331\/07\u201307-2021, and Italy (Ministry of Health, General Directorate of Animal Health and Veterinary Medicines) under reference no. S20164-00. All owners signed informed consent after having all study details explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RC, EZ, and LH are employees of the sponsor (MSD). DO, DR, EP, MBS, and ZK were commissioned by MSD to conduct the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}